BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 02/24/25
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 toGlobeNewsWire • 02/24/25
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint CongressGlobeNewsWire • 02/10/25
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)GlobeNewsWire • 01/10/25
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/24
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%Zacks Investment Research • 10/23/24
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)GlobeNewsWire • 10/14/24
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeGlobeNewsWire • 10/02/24
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileGlobeNewsWire • 09/30/24
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksGlobeNewsWire • 09/17/24
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumGlobeNewsWire • 09/06/24
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/05/24
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/24
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/24
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 07/29/24